Literature DB >> 11982509

Tumour implantation following laparoscopy using different insufflation gases.

Anurag Gupta1, David I Watson, Tanya Ellis, Glyn G Jamieson.   

Abstract

BACKGROUND: Because of the possibility of intraperitoneal seeding and port-site recurrences following laparoscopic surgery, the role of laparoscopy in cancer surgery remains controversial. Previous experimental studies have suggested that chemical, metabolic and immunological changes following carbon dioxide (CO2) insufflation may be responsible for this phenomenon. Earlier experimental studies done by the University of Adelaide Department of Surgery have also shown that helium insufflation is associated with none of the adverse changes brought about by CO2 insufflation. Helium insufflation is also associated with lower rates of intra-abdominal tumour spread. The aim of this study was to determine whether these identified benefits apply to inert gases in general.
METHODS: Twenty-four Dark Agouti rats were randomized to undergo laparoscopy with 40 min insufflation using one of the following four gases (six rats in each group); CO2, helium, argon and nitrogen. A tumour cell suspension was injected into the abdominal cavity at the beginning of laparoscopy. The rats were killed 7 days after surgery, and the peritoneal cavity and port sites were examined for the presence of tumour.
RESULTS: Rats undergoing helium insufflation, had the least number of port-site recurrences and the least amount of intraperitoneal tumour spread. Argon and nitrogen pneumoperitoneum were associated with a large number of port-site recurrences and widespread tumour seeding. The effect of CO2 insufflation was intermediate.
CONCLUSION: The choice of insufflation gas influences the incidence of port-site metastases and the degree of intraperitoneal tumour spread following laparoscopic cancer surgery. The reduced port-site recurrences and intraperitoneal spread that followed helium pneumoperitoneum is likely to be a unique property of this gas rather than a property of inert gases in general.

Entities:  

Mesh:

Year:  2002        PMID: 11982509     DOI: 10.1046/j.1445-2197.2002.02385.x

Source DB:  PubMed          Journal:  ANZ J Surg        ISSN: 1445-1433            Impact factor:   1.872


  7 in total

1.  Subcutaneous metastasis at a surgical drain site after the resection of pancreatic cancer.

Authors:  Shawn D St Peter; Cuong C Nguyen; David C Mulligan; Adyr A Moss
Journal:  Int J Gastrointest Cancer       Date:  2003

2.  Treatment of Early Stage High-Risk Endometrioid-Type Endometrial Cancer and Patterns of Disease Relapse: A Retrospective Analysis.

Authors:  Jiheon Song; Tien Le; Laura Hopkins; Michael Fung-Kee-Fung; Alborz Jooya; Krystine Lupe; Marc Gaudet; Rajiv Samant
Journal:  Adv Radiat Oncol       Date:  2020-08-06

3.  Influence of different gases used for laparoscopy (helium, carbon dioxide, room air, xenon) on tumor volume, proliferation, and apoptosis.

Authors:  S Dähn; P Schwalbach; F Wöhleke; A Benner; C Kuntz
Journal:  Surg Endosc       Date:  2003-08-15       Impact factor: 4.584

4.  Low incidence of port-site metastasis after robotic assisted surgery for endometrial cancer staging: descriptive analysis.

Authors:  D Barraez; H Godoy; T McElrath; D Kredentser; P Timmins
Journal:  J Robot Surg       Date:  2014-11-05

5.  Port-site metastasis after laparoscopic surgery for urological malignancy: forgotten or missed.

Authors:  N Kadi; M Isherwood; M Al-Akraa; S Williams
Journal:  Adv Urol       Date:  2012-04-10

6.  Inhibition of peritoneal dissemination of colon cancer by hyperthermic CO2 insufflation: A novel approach to prevent intraperitoneal tumor spread.

Authors:  Yuanfei Peng; Hua Yang; Qing Ye; Houming Zhou; Minhua Zheng; Yinghong Shi
Journal:  PLoS One       Date:  2017-02-16       Impact factor: 3.240

7.  Targeting Myeloid-Derived Suppressor Cells Derived From Surgical Stress: The Key to Prevent Post-surgical Metastasis.

Authors:  Sha Zhu; Yunuo Zhao; Yuxin Quan; Xuelei Ma
Journal:  Front Surg       Date:  2021-12-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.